How European MidPharmas have Grown Profits (MedNous)

Europe is home to 85 mid-sized pharmaceutical companies (MidPharmas) that invest in developing and commercialising pharmaceutical products. Many of these companies have achieved impressive, upward-trending earnings before interest and tax (EBIT) margins in the last five years. The median EBIT margin of MidPharma is now comparable to that of the largest pharma companies and many MidPharmas now out-perform their larger rivals on measures of both profitability and revenue growth. The reason is straightforward: the mid-sized companies have a strong strategic focus.

We explore how a clear strategy has enabled MidPharmas to evolve effective operating models and outperform their larger rivals in the latest edition of MedNous.

© 2022 Evernow Publishing Ltd

Reprinted with permission from MedNous, April 2022 (

For further insights into Europe’s MidPharmas, we examine this microcosm of the global industry and analyse how these companies thrive in our latest European MidPharma Report.